Product Details
| Product Name:
JNJ0966 |
CAS No.:
315705-75-0 |
| Purity:
99.48% |
Supply Ability:
10g |
| Release date:
2025/04/30 |
Product Introduction
Bioactivity
| Name | JNJ0966 |
| Description | JNJ0966 is a highly selective [MMP-9 zymogen] inhibitor with an IC50 of 440 nM. |
| In vitro | The activations of proMMP-1, proMMP-2, and proMMP-3 are not significantly different in the presence or absence of 10 μM JNJ0966, whereas proMMP-9 activation by trypsin is significantly attenuated by JNJ0966. The addition of JNJ0966 to the reaction results in a significant reduction in fully processed MMP-9 and an apparent accumulation of the intermediate species[1]. |
| In vivo | JNJ0966 demonstrated effectiveness in alleviating the severity of disease in a mouse model of experimental autoimmune encephalomyelitis. Its effectiveness is dose-dependent, showing plasma and brain concentrations of 77.5±31.1 ng/mL (215 nM) and 481.6±162.5 ng/g (~1336 nM) at a 10-mg/kg dose, and 293.6±118.4 ng/mL (815 nM) in plasma and 1394.0±649.1 ng/g (~3867 nM) in the brain at a 30-mg/kg dose, respectively. Moreover, JNJ0966 exhibits a preference for accumulation in the brain, evidenced by brain/plasma ratios of 6.2 at the 10 mg/kg dose and 4.7 at the 30 mg/kg dose. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 150 mg/mL (416.15 mM), Sonication is recommended.
|
| Keywords | MMP-9 | MMP | Matrix metalloproteinases | JNJ-0966 | JNJ0966 | JNJ 0966 | Inhibitor | inhibit |
| Inhibitors Related | Stigmasterol | Ethyl gallate | Doxycycline (hyclate) | Astragaloside IV | Doxycycline | Edaravone | Glucosamine | Bovine Type II Collagen | Triolein | Arctigenin | Fenofibric acid | Glucosamine sulfate |
| Related Compound Libraries | Highly Selective Inhibitor Library | Target-Focused Phenotypic Screening Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Protease Inhibitor Library | Angiogenesis related Compound Library | Inhibitor Library | Anti-Fibrosis Compound Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:1260907-17-2
$36.00 / 1mg
-
CAS:15658-35-2
$62.00 / 10mg
-
CAS:24424-99-5
$0.00 / 1removed
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States